LakeShore Dividend Paid And Capex Coverage Ratio from 2010 to 2024
| LSB Stock | 2.75 0.23 7.72% |
Dividend Paid And Capex Coverage Ratio | First Reported 2010-12-31 | Previous Quarter (6.67) | Current Value (7.01) | Quarterly Volatility 1.75009346 |
Check LakeShore Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among LakeShore Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 37.9 M, Interest Expense of 29.6 M or Selling General Administrative of 130.7 M, as well as many indicators such as Price To Sales Ratio of 9.29, Dividend Yield of 0.0 or PTB Ratio of 9.1. LakeShore financial statements analysis is a perfect complement when working with LakeShore Biopharma Valuation or Volatility modules.
LakeShore | Dividend Paid And Capex Coverage Ratio |
Latest LakeShore Biopharma's Dividend Paid And Capex Coverage Ratio Growth Pattern
Below is the plot of the Dividend Paid And Capex Coverage Ratio of LakeShore Biopharma Co, over the last few years. It is LakeShore Biopharma's Dividend Paid And Capex Coverage Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LakeShore Biopharma's overall financial position and show how it may be relating to other accounts over time.
| Dividend Paid And Capex Coverage Ratio | 10 Years Trend |
|
Dividend Paid And Capex Coverage Ratio |
| Timeline |
LakeShore Dividend Paid And Capex Coverage Ratio Regression Statistics
| Arithmetic Mean | (2.85) | |
| Coefficient Of Variation | (61.41) | |
| Mean Deviation | 1.11 | |
| Median | (2.35) | |
| Standard Deviation | 1.75 | |
| Sample Variance | 3.06 | |
| Range | 7.0079 | |
| R-Value | (0.49) | |
| Mean Square Error | 2.52 | |
| R-Squared | 0.24 | |
| Significance | 0.07 | |
| Slope | (0.19) | |
| Total Sum of Squares | 42.88 |
LakeShore Dividend Paid And Capex Coverage Ratio History
About LakeShore Biopharma Financial Statements
LakeShore Biopharma stakeholders use historical fundamental indicators, such as LakeShore Biopharma's Dividend Paid And Capex Coverage Ratio, to determine how well the company is positioned to perform in the future. Although LakeShore Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in LakeShore Biopharma's assets and liabilities are reflected in the revenues and expenses on LakeShore Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in LakeShore Biopharma Co,. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | (6.67) | (7.01) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether LakeShore Biopharma Co, is a strong investment it is important to analyze LakeShore Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact LakeShore Biopharma's future performance. For an informed investment choice regarding LakeShore Stock, refer to the following important reports:Check out the analysis of LakeShore Biopharma Correlation against competitors. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LakeShore Biopharma. If investors know LakeShore will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about LakeShore Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Revenue Per Share 5.363 | Quarterly Revenue Growth 0.277 | Return On Assets (0.14) | Return On Equity (0.66) |
The market value of LakeShore Biopharma Co, is measured differently than its book value, which is the value of LakeShore that is recorded on the company's balance sheet. Investors also form their own opinion of LakeShore Biopharma's value that differs from its market value or its book value, called intrinsic value, which is LakeShore Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because LakeShore Biopharma's market value can be influenced by many factors that don't directly affect LakeShore Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between LakeShore Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if LakeShore Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, LakeShore Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.